Open Minds on Avandia? A Defining Challenge for the New Regulatory Climate
This article was originally published in RPM Report
Executive Summary
The run-up to FDA's re-review of Avandia is becoming highly charged. There is a lot riding on the outcome of the agency's decision on how to deal with the diabetes therapy. Here are a number of considerations to think about going into FDA's advisory committee meeting.